Drug Profile


Alternative Names: DDP 733; MKC 733

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mitsubishi Chemical
  • Developer Dynogen Pharmaceuticals; Edusa Pharmaceuticals; Mitsubishi Chemical
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Laxatives; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 5-HT3 receptor-partial-agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Constipation; Dyspepsia; Gastro-oesophageal reflux; Irritable bowel syndrome; Reflux oesophagitis

Most Recent Events

  • 12 Jul 2010 Phase-II clinical trials in Gastro-oesophageal reflux in USA (PO)
  • 22 May 2008 Final safety and efficacy data from a phase IIa (IBS-c) trial in Irritable bowel syndrome presented at the Digestive Disease Week 2008 (DDW-2008) ,
  • 09 Nov 2007 Phase-II clinical trials in Irritable bowel syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top